A detailed history of Legal & General Group PLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Legal & General Group PLC holds 97,380 shares of BPMC stock, worth $9.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
97,380
Previous 97,380 -0.0%
Holding current value
$9.4 Million
Previous $9 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $421,425 - $603,825
5,011 Added 5.42%
97,380 $9 Million
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $2.8 Million - $3.58 Million
32,870 Added 55.24%
92,369 $9.96 Million
Q1 2024

May 14, 2024

BUY
$73.17 - $99.79 $39,145 - $53,387
535 Added 0.91%
59,499 $5.64 Million
Q4 2023

Feb 15, 2024

BUY
$43.96 - $92.84 $22,331 - $47,162
508 Added 0.87%
58,964 $5.44 Million
Q3 2023

Nov 14, 2023

BUY
$46.9 - $66.0 $27,764 - $39,072
592 Added 1.02%
58,456 $2.94 Million
Q2 2023

Aug 14, 2023

SELL
$42.2 - $66.37 $16,837 - $26,481
-399 Reduced 0.68%
57,864 $3.66 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $183,167 - $241,200
4,824 Added 9.03%
58,263 $2.62 Million
Q4 2022

Feb 14, 2023

SELL
$41.06 - $66.48 $1,313 - $2,127
-32 Reduced 0.06%
53,439 $2.34 Million
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $61,763 - $96,114
-1,237 Reduced 2.26%
53,471 $3.52 Million
Q2 2022

Aug 22, 2022

BUY
$45.23 - $70.15 $60,789 - $94,281
1,344 Added 2.52%
54,708 $2.76 Million
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $23,263 - $47,334
430 Added 0.81%
53,364 $3.41 Million
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $61,828 - $76,089
656 Added 1.25%
52,934 $5.67 Million
Q3 2021

Nov 15, 2021

BUY
$80.98 - $109.47 $875,150 - $1.18 Million
10,807 Added 26.06%
52,278 $5.37 Million
Q2 2021

Aug 12, 2021

BUY
$82.78 - $101.0 $491,050 - $599,132
5,932 Added 16.69%
41,471 $3.65 Million
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $56,875 - $67,891
627 Added 1.8%
35,539 $3.46 Million
Q4 2020

Feb 12, 2021

BUY
$92.08 - $124.48 $102,669 - $138,795
1,115 Added 3.3%
34,912 $3.92 Million
Q3 2020

Nov 13, 2020

SELL
$66.45 - $92.7 $148,848 - $207,648
-2,240 Reduced 6.22%
33,797 $3.13 Million
Q2 2020

Aug 14, 2020

BUY
$57.09 - $79.27 $33,683 - $46,769
590 Added 1.66%
36,037 $2.81 Million
Q1 2020

May 14, 2020

BUY
$48.11 - $82.22 $122,439 - $209,249
2,545 Added 7.74%
35,447 $2.07 Million
Q4 2019

Feb 13, 2020

BUY
$66.73 - $82.59 $416,195 - $515,113
6,237 Added 23.39%
32,902 $2.64 Million
Q3 2019

Nov 13, 2019

BUY
$72.9 - $101.41 $252,088 - $350,675
3,458 Added 14.9%
26,665 $1.96 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $221,134 - $294,084
3,007 Added 14.89%
23,207 $2.19 Million
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $173,615 - $308,729
3,565 Added 21.43%
20,200 $1.62 Million
Q4 2018

Feb 15, 2019

BUY
$45.57 - $74.26 $45,342 - $73,888
995 Added 6.36%
16,635 $897,000
Q2 2018

Aug 10, 2018

SELL
$60.96 - $101.18 $77,175 - $128,093
-1,266 Reduced 7.49%
15,640 $992,000
Q1 2018

May 17, 2018

SELL
$73.28 - $102.95 $75,918 - $106,656
-1,036 Reduced 5.77%
16,906 $1.55 Million
Q4 2017

Feb 13, 2018

BUY
$62.91 - $88.32 $1.13 Million - $1.58 Million
17,942
17,942 $1.36 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.76B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.